Reference
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study Lancet : 6 Apr 2022. Available from: URL: https://doi.org/10.1016/S0140-67362200456-1
Rights and permissions
About this article
Cite this article
Asundexian reduces haemorrhage versus apixaban. Reactions Weekly 1902, 4 (2022). https://doi.org/10.1007/s40278-022-13148-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-13148-y